Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials
Maria M. Simile, Paola Bagella, Gianpaolo Vidili, et al.
Medicina (2019) Vol. 55, Iss. 2, pp. 42-42
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

An atlas of human metabolism
Jonathan L. Robinson, Pınar Kocabaş, Hao Wang, et al.
Science Signaling (2020) Vol. 13, Iss. 624
Open Access | Times Cited: 334
Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies
Ali Alqahtani, Zubair Khan, Abdurahman Alloghbi, et al.
Medicina (2019) Vol. 55, Iss. 9, pp. 526-526
Open Access | Times Cited: 228
The Tumor Microenvironment in Cholangiocarcinoma Progression
Luca Fabris, Keisaku Sato, Gianfranco Alpini, et al.
Hepatology (2020) Vol. 73, Iss. S1, pp. 75-85
Open Access | Times Cited: 150
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
Sara S. Fois, Panagiotis Paliogiannis, Angelo Zinellu, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 612-612
Open Access | Times Cited: 126
Progress in refining the clinical management of cancer of unknown primary in the molecular era
Elie Rassy, Nicholas Pavlidis
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 9, pp. 541-554
Closed Access | Times Cited: 89
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Sara Massironi, Lorenzo Pilla, Alessandra Elvevi, et al.
Cells (2020) Vol. 9, Iss. 3, pp. 688-688
Open Access | Times Cited: 74
Biliary Tract Cancer: Current Medical Treatment Strategies
Ester Oneda, Mohammad Abu Hilal, Alberto Zaniboni
Cancers (2020) Vol. 12, Iss. 5, pp. 1237-1237
Open Access | Times Cited: 58
Cancer-Associated Fibroblast-Derived IL-6 Determines Unfavorable Prognosis in Cholangiocarcinoma by Affecting Autophagy-Associated Chemoresponse
Suyanee Thongchot, Chiara Vidoni, Alessandra Ferraresi, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2134-2134
Open Access | Times Cited: 44
Prognostic and Predictive Molecular Markers in Cholangiocarcinoma
Sandra Pavicevic, Sophie Reichelt, Deniz Uluk, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 1026-1026
Open Access | Times Cited: 31
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
Amol Gupta, Razelle Kurzrock, Jacob J. Adashek
Cancers (2023) Vol. 15, Iss. 5, pp. 1578-1578
Open Access | Times Cited: 17
LncRNA TTN-AS1 promotes the progression of cholangiocarcinoma via the miR-320a/neuropilin-1 axis
Huaqiang Zhu, Bo Zhai, Changjun He, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 8
Open Access | Times Cited: 38
Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression
Alphonse E. Sirica, Mario Strazzabosco, Massimiliano Cadamuro
Advances in cancer research (2020), pp. 321-387
Open Access | Times Cited: 38
Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma
Raluca Maria Fostea, Elisa Fontana, Gonzalo Torga, et al.
Cancers (2020) Vol. 12, Iss. 9, pp. 2599-2599
Open Access | Times Cited: 35
Cholangiocarcinoma: novel therapeutic targets
Keisaku Sato, Shannon Glaser, Domenico Alvaro, et al.
Expert Opinion on Therapeutic Targets (2020) Vol. 24, Iss. 4, pp. 345-357
Open Access | Times Cited: 33
Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
Su Min Cho, Abdullah Esmail, Ali Raza, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2641-2641
Open Access | Times Cited: 22
Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
Ying Zhang, Ran Li, Yongchao Liang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 11
Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma
Héctor Perez‐Montoyo
Cells (2020) Vol. 9, Iss. 3, pp. 614-614
Open Access | Times Cited: 31
Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate
Viet Ha Le, Victoria O’Connor, Daneng Li, et al.
Journal of Surgical Oncology (2020) Vol. 123, Iss. 1, pp. 164-171
Closed Access | Times Cited: 31
The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
Antonio Cigliano, Shanshan Zhang, Silvia Ribback, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 19
Isoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism
Lijun Zhao, Haonan Qi, Wei-Ting Liu, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
<p>Anisodamine Suppressed the Growth of Hepatocellular Carcinoma Cells, Induced Apoptosis and Regulated the Levels of Inflammatory Factors by Inhibiting NLRP3 Inflammasome Activation</p>
Ping Li, Yu Liu, Qiang He
Drug Design Development and Therapy (2020) Vol. Volume 14, pp. 1609-1620
Open Access | Times Cited: 24
Quality of Life and Symptom Management in Advanced Biliary Tract Cancers
Lindsay Hunter, Heloisa P. Soares
Cancers (2021) Vol. 13, Iss. 20, pp. 5074-5074
Open Access | Times Cited: 23
miR-186 Suppresses the Progression of Cholangiocarcinoma Cells Through Inhibition of Twist1
Ming Zhang, Baochang Shi, Kai Zhang
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2019) Vol. 27, Iss. 9, pp. 1061-1068
Open Access | Times Cited: 23
Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma
Yuanwen Zheng, Yejun Qin, Wei Gong, et al.
Journal of Gastrointestinal Oncology (2021) Vol. 12, Iss. 6, pp. 2631-2642
Open Access | Times Cited: 19
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Caterina Arru, Maria R. De Miglio, Antonio Cossu, et al.
Advances in Therapy (2021) Vol. 38, Iss. 7, pp. 3674-3693
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top